SynchNeuro, Inc.

We had a great #HLTHUSA meeting this week! Thanks to all who stopped by the SynchNeuro, Inc. booth and presentation to learn about our vision for brain signal-based non-invasive glucose monitoring. Emily Mirro

We’re heading to Las Vegas for HLTH USA next week! Come find us in the StartUp Health Pavilion and catch Emily Mirro presenting on the Demo Stage Monday at 12:40 PM.

Congratulations to our founder Casey Halpern! 🎉 Dr. Halpern has received the 2025 NIH Director’s Pioneer Award to advance his vision of developing innovative, less invasive technologies to treat complex brain disorders such as depression, OCD, and substance use disorder. We’re inspired by Casey's leadership and dedication to transforming brain health. https://lnkd.in/gYDT_d3u

Our president Emily Mirro will be joining the Brain Health Tech panel at The MedTech Conference on October 6th along with Marc Powell from Reach Neuro, Inc., John Forrest from VERAVAS, Inc. and Ken Mariash from Sinaptica Therapeutics. Come hear their thoughts on the future of brain health and neurotech! SynchNeuro, Inc. MedTech Innovator American Heart Association

In this recent episode of "The Hard Things About Healthcare" with Ginger Vieira, our founder Dr. Casey Halpern highlights a challenge we think about every day at SynchNeuro, Inc.: bridging the gap between breakthrough science and consumer health. In the conversation, Casey shares his vision for revolutionizing how people interact with and monitor their metabolic health through our non-invasive, brain-based glucose monitor. https://lnkd.in/gAYCGfpV

SynchNeuro, Inc. will be exhibiting at the HLTH USA meeting. Please reach out in advance if you would like to set up a meeting or stop by our booth.

SynchNeuro, Inc. is developing the world’s first non-invasive brain signal-based glucose monitor to help people take control of their metabolic health and avoid or reverse diabetes. Casey Halpern Heonsoo Lee MedTech Innovator https://lnkd.in/gBMxSWey

We are proud to share that SynchNeuro, Inc. has been selected to join the American Heart Association’s Women’s Heart and Brain Health Accelerator — a new initiative driving innovation at the intersection of cardiology, neuroscience, and women’s health. Our mission is to advance non-invasive brain technology to improve health outcomes, and we’re honored to be part of this cohort of forward-thinking startups tackling critical challenges in cardiovascular and neurological care. Thank you to American Heart Association Ventures for this opportunity. We’re excited for what’s ahead! #WomensHealth #BrainHealth #HeartHealth #AHAAccelerator https://lnkd.in/eT3TB8b8

New CDC data shows 1 in 3 U.S. teens now have prediabetes. That’s over 8 million adolescents with elevated blood sugar—putting them at risk for Type 2 diabetes, heart disease, and stroke. At SynchNeuro, Inc., we believe early intervention is critical. Prediabetes is a warning sign, and it’s one we can’t afford to ignore. Let’s keep pushing for solutions that support metabolic health from the start! #Prediabetes #TeenHealth #Prevention #SynchNeuro https://lnkd.in/eC2s33jT

SynchNeuro, Inc. has been selected as one of the 5 finalists in the Diabetes Center Berne Innovation Challenge! Thank you to the judges and organizers — we are excited for what’s ahead. Diabetes Technology Society (DTS) Casey Halpern Heonsoo Lee https://lnkd.in/gt--JN8D